ZZ-FIRST

A BIOMARKER–DISCOVERY PHASE II TRIAL OF ENZALUTAMIDE AND TALAZOPARIB (PF-06944076) FOR THE TREATMENT OF METASTATIC HORMONE–NAÏVE PROSTATE CANCER. MEDOPP234 – ZZFIRST (EUDRACT# 2019-003096-20)

ZZFIRST IS A MULTICENTER, OPEN-LABEL, RANDOMIZED, TWO-ARM, PHASE II CLINICAL TRIAL IN MEN WITH METASTATIC HORMONE–NAÏVE PROSTATE CANCER (MHNPC). THE PRIMARY GOAL IS TO EVALUATE THE ANTITUMOR ACTIVITY OF TALAZOPARIB (PF-06944076) IN COMBINATION WITH ENZALUTAMIDE AND ADT -AS DETERMINED BY THE CONFIRMED PROSTATE-SPECIFIC ANTIGEN-COMPLETE RESPONSE (PSA-CR)- IN PATIENTS WITH METASTATIC HORMONE–NAÏVE PROSTATE CANCER (MHNPC).

https://clinicaltrials.gov/study/NCT04332744

COUNTRY

STATUS

TUMOR TYPE

PHASE

SITES

mHNPC

Spain

Analysis

CLINICAL TRIAL DETAILS

PRESS RELEASE

2021 Press Release: https://www.medsir.org/post/zzfirst-study-prostate

SCIENTIFIC IMPACT

ASCO 2026 presentation: https://www.medsir.org/_files/ugd/39f166_ee800ba338fb423a9097b2d8a3f8f0be.pdf | ESMO 2024 poster: https://www.medsir.org/_files/ugd/39f166_3d80367374094a369cd3eb577fcf9c39.pdf | ESMO 2024 lay language summary: https://www.medsir.org/_files/ugd/39f166_2c52ed4bf2bf43b9a4d2ac2f6ce98964.pdf | ASCO GU 2022 poster: https://39f1664e-7766-40bf-9b5a-e3575d54bba6.usrfiles.com/ugd/39f166_0ba640fb87bc4d53b70176b3a1466435.pdf

BLOG ARTICLES RELATED

MEDSIR’s Experience at ASCO GU 2022: Update on our 2 GU trials: https://www.medsir.org/post/medsir-s-experience-at-asco-gu-2022-update-on-our-2-gu-trials | We’re presenting at ASCO GU 2022!: https://www.medsir.org/post/we-re-presenting-at-asco-gu-2022 | It’s that time of year again! It’s MOVEMBER!: https://www.medsir.org/post/it-s-that-time-of-year-again-it-s-movember | First Patient Enrolled In ZZ-First Study: https://www.medsir.org/post/first-patient-enrolled-in-zz-first-study | ZZ-FIRST study Approval: https://www.medsir.org/post/aemps-and-celm-zzfirst-study-submission

TRIAL SITES

Hospital Universitari Vall D'Hebrón (Spain) | Hospital Clínic i Provincial de Barcelona (Spain) | Hospital Universitario 12 de Octubre (Spain) | Institut Català d'Oncologia Badalona (ICO) (Spain) | Hospital del Mar (Spain) | Hospital Universitario Miguel Servet (Spain) | Instituto Valenciano de Oncología (IVO) (Spain) | Hospital Provincial de Castellón (Spain) | Hospital Universitario Virgen de la Victoria (Spain)

Dr. Cortes and Dr. Llombart PHERain interview

Beyond Chemotherapy

Dr. Vanes Quiroga

Dr. Sofia Braga

Dr. Silvi Antolín

Dr. Escrivá de Romaní

Dr. Philipp Aftimos

Dr. Manuel Ruiz

Prof. Daniele Generali PHEGain interview

Dr. Jacques Medioni

Dr. Dunca Wheatley